New Directions in Long-Acting ART and Long-Acting PrEP

Volume 9, Issue 12

New Directions in Long-Acting ART and Long-Acting PrEP

In this issue:

How will the current research advancements in long-acting ART affect clinicians’ ability to provide better care for their patients with HIV? The recent data show that the low uptake and adherence to PrEP may be largely due to the pill burden and potential stigma of daily dosing. How might the newer longer-acting PrEP regimens challenge this reluctance?

Join us as we discuss these issues our guests from the Johns Hopkins University School of Medicine — Dr. Ethel Weld from the Divisions of Clinical Pharmacology and Infectious Disease, and Dr. Michael Rose, Assistant Chief of Service of the Thayer Firm — in this issue of eHIV Review.

Learning objective:

Describe the evidence and potential indications for new and emerging ART and PrEP options.

Authors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Michael Rose, MD

Instructor of Medicine
Assistant Chief of Service of the Thayer Firm
Johns Hopkins University School of Medicine
Baltimore, MD

Guest Faculty Disclosures

Dr. Weld and Dr. Rose have indicated that they have no financial interests or relationships with an ineligible company.

Unlabeled/Unapproved Uses

Dr. Weld and Dr. Rose have indicated that they will reference the unlabeled/unapproved uses of lenacapavir and longer-acting cabotegravir for PrEP, lenacapavir plus islatravir for ART, and cabotegravir/rilpivirine for people with viremia.

Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Guest Faculty Disclosures:

Dr. Weld and Dr. Rose have indicated that they have no financial interests or relationships with an ineligible company.

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 28, 2025
Expiration date: March 27, 2027

Start Issue